MRI of the Liver With Eovist
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)|
- Accuracy of a new MR protocol in diagnosing HCC and other liver lesions. [ Time Frame: One day: participants will have one MRI of the liver. ] [ Designated as safety issue: No ]
|Study Start Date:||August 2010|
|Study Completion Date:||January 2012|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence of Hepatitis B and C which are known to promote HCC. Patients have a better prognosis (survival outlook) if HCC is found and treated at an early stage. MRI is the best imaging modality for diagnosing HCC.
This study will compare standard MRIs and MRIs performed with a newly developed MR protocol to determine if it is possible to more confidently diagnose HCC.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01215838
|Principal Investigator:||Orpheus Kolokythas, MD||University of Washington|